Interleukin-25 negatively controls pathogenic responses in the gut.
Inflamm Allergy Drug Targets
; 10(3): 187-91, 2011 Jun.
Article
em En
| MEDLINE
| ID: mdl-21428908
ABSTRACT
Although interleukin-25 (IL-25) has been traditionally considered as a cytokine involved in T helper (Th) 2 cell-associated allergic diseases and host defence against helminthic parasites, recent studies have shown that IL-25 exerts negative effects on the initiation and progression of Th1/Th17-mediated pathologies. This later function of IL-25 is particularly evident at the gut level, where IL-25 could contribute to attenuate tissue-damaging immune responses. These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Colite Ulcerativa
/
Doença de Crohn
/
Interleucina-17
/
Imunoterapia
/
Mucosa Intestinal
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article